Pancreatic Cancer Research

ResearcherStanford MedicineActive in the last 2 years

Teri A. Longacre

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-0935-7300; OpenAlex author ID A5089159861. Sources: ClinicalTrials.gov.

Their work

Papers
7
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2010: 1 trial · 2011: none · 2012: none · 2013: none · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 7

  1. Claudin-18.2 immunohistochemical evaluation in pancreatic cancer specimens: review and recommendations for routine testing and scoring. Co-author DOI 10.1007/s00428-025-04222-2↗
  2. Hematoxylin and Eosin Architecture Uncovers Clinically Divergent Niches in Pancreatic Cancer. Co-author DOI 10.1089/ten.tea.2024.0039↗
  3. Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.xcrm.2023.101248↗
  4. Detection of visually occult metastatic lymph nodes using molecularly targeted fluorescent imaging during surgical resection of pancreatic cancer. Co-author DOI 10.1016/j.hpb.2018.11.008↗
  5. Intraoperative Pancreatic Cancer Detection using Tumor-Specific Multimodality Molecular Imaging. Co-author DOI 10.1245/s10434-018-6453-2↗
  6. A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.09.007↗
  7. Pancreatic Cancer Surgical Resection Margins: Molecular Assessment by Mass Spectrometry Imaging. Co-author DOI 10.1371/journal.pmed.1002108↗

Trials 1

  1. Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers Principal investigator NCT01031056↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jeffrey Allen Norton · 3 shared papers, 2016–2024 · strength 0.37
  2. Deshka S. Foster · 2 shared papers, 2023–2024 · strength 0.31
  3. Daniel Delitto · 2 shared papers, 2023–2024 · strength 0.31
  4. Jason L. Guo · 2 shared papers, 2023–2024 · strength 0.31
  5. Shamik Mascharak · 2 shared papers, 2023–2024 · strength 0.31
  6. Michael Thornton Longaker · 2 shared papers, 2023–2024 · strength 0.31
  7. Matteo Fassan · 1 shared paper, 2025 · strength 0.27
  8. Manabu Takamatsu · 1 shared paper, 2025 · strength 0.27
  9. Claudio Luchini · 1 shared paper, 2025 · strength 0.27
  10. George A. Poultsides · 3 shared papers, 2016–2019 · strength 0.21
  11. Eben Lloyd Rosenthal · 2 shared papers, 2018–2019 · strength 0.15
  12. Willemieke S. F. J. Tummers · 2 shared papers, 2018–2019 · strength 0.15
  13. Bert A. Bonsing · 2 shared papers, 2018–2019 · strength 0.15
  14. George Albert Fisher · 2 shared papers, 2018–2019 · strength 0.15
  15. Sanjiv Sam Gambhir · 2 shared papers, 2018–2019 · strength 0.15
  16. Rutger‐Jan Swijnenburg · 2 shared papers, 2018–2019 · strength 0.15
  17. Alexander L. Vahrmeijer · 2 shared papers, 2018–2019 · strength 0.15
  18. Livia Schiavinato Eberlin · 1 shared paper, 2016 · strength 0.06
  19. Albert C. Koong · 1 shared paper, 2017 · strength 0.05
  20. Brittany M. Flowers · 1 shared paper, 2017 · strength 0.05
  21. Stephano S. Mello · 1 shared paper, 2017 · strength 0.05
  22. Margaret M. Kozak · 1 shared paper, 2017 · strength 0.05
  23. Daniel Tandel Chang · 1 shared paper, 2017 · strength 0.05
  24. Laura DeLong Wood · 1 shared paper, 2017 · strength 0.05
  25. Ralph H. Hruban · 1 shared paper, 2017 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.